Estradiol/DRSP (Angeliq, BAY86-4891)

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
82
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Postmenopause

Conditions

Postmenopause

Trial Timeline

Sep 1, 2005 โ†’ Dec 1, 2006

About Estradiol/DRSP (Angeliq, BAY86-4891)

Estradiol/DRSP (Angeliq, BAY86-4891) is a approved stage product being developed by Bayer for Postmenopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00185328. Target conditions include Postmenopause.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00185328ApprovedCompleted